The panel of modulators include the standard‐of‐care therapies for HCC, sorafenib and cabozantinib, as well as SSOs against four synthetic lethal genes of MYC–CHEK1, MAX, MCL1, and BRD4 (ssCHK1, ssMAX, ssMCL1, ssBRD4).10, 15, 16, 23, 49, 50. The gene discussed is BRD4; the disease is hepatocellular carcinoma.